Diabetic papillopathy treated with intravitreal ranibizumab

Yıldırım, Mehmet; Kılıç, Deniz; Dursun, Mehmet; Dursun, Birgül

doi:10.2147/imcrj.s132479

Cited by 13 publications

(4 citation statements)

References 10 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetic papillopathy can be seen in both mild and severe diabetic retinopathy ( 4 ). In many cases in the literature, visual acuity increased after papillary edema resolved.…”

Section: Discussionmentioning

confidence: 99%

Bilateral hypertensive papillopathy with diffuse retinal telangiectasis

Limon¹

2022

Beyoglu Eye J

View full text Add to dashboard Cite

A 16-year-old type 1 diabetic female patient was consulted to our clinic for acute bilateral painless vision loss with a 2-week history in the right eye and a 1-week history in the left eye. At the initial visit, the best-corrected visual acuity was 0.2 in the right eye and 0.05 in the left eye. In fundus examination, both optic disks were pale and slightly swollen. In both eyes, superficial telangiectatic vessels were extending from the optic disk to the retina. Telangiectatic vessels disappeared within 10 days with systemic hypertension regulation and without any ocular treatment.

show abstract

“…Diabetic papillopathy can be seen in both mild and severe diabetic retinopathy ( 4 ). In many cases in the literature, visual acuity increased after papillary edema resolved.…”

Section: Discussionmentioning

confidence: 99%

Bilateral hypertensive papillopathy with diffuse retinal telangiectasis

Limon¹

2022

Beyoglu Eye J

View full text Add to dashboard Cite

show abstract

“…The actual literature provides numerous papers reporting on the efficacy of anti-VEGF agents while accentuating the role of VEGF in the vascular permeability of telangiectatic disc vessels and macular capillaries, given that ME is a common finding in more than half of DP patients [ 20 – 23 ]. The common denominator of these cases is represented by the mild-to-moderate grade of severity of DP, the baseline BCVA > 0.1, and the lack of macular edema.…”

Section: Discussionmentioning

confidence: 99%

Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports

Arapi

Neri²,

Giovannini

et al. 2021

J Med Case Reports

View full text Add to dashboard Cite

Background Diabetic papillopathy is a rare diagnosis of exclusion characterized by unilateral or bilateral optic disc edema with variable degrees of visual loss. Although the visual prognosis has been generally reported as favorable, the presence of severe disc edema associated with macular edema prompts the need for treatment. We present a specific and unreported therapeutic approach consisting of intravitreal aflibercept and subtenon triamcinolone acetonide injections in two patients with evidence of diabetic papillopathy and macular edema. Case presentation In the first case, a 60-year-old Caucasian woman affected by type II diabetes mellitus presented with fundoscopic evidence of sequential bilateral optic disc edema associated with acute severe visual loss in both eyes. The second patient, a diabetic 57-year-old Caucasian male, presented with sudden painless visual loss in his left eye. Multimodal imaging and systemic findings correlated towards an infrequent diagnosis of diabetic papillopathy. In a period of 5–7 weeks after treatment, both patients experienced almost full visual and anatomical recovery. A steady situation was observed at 12 months of follow-up. Conclusions Both our cases displayed a severe grade of optic disc edema, which was optimally reversed with intravitreal aflibercept and subtenon triamcinolone acetonide leading to a relatively rapid and safe improvement in visual acuity.

show abstract

“…Several case reports describe the use of intravitreal corticosteroids or anti vascular endothelial growth factor. Previous case studies have shown improvement in optic disc oedema and improvement in visual acuity using intravitreal injections such as intravitreal injections of triamcinolone acetate, intravitreal injections of bevacizumab (Avastin) or ranizumab, and periocular corticosteroids(Al-hinai, Al-abri, and Al-hajri 2011) (Yildirim et al 2017). The most significant determinant is efforts to control either the patient's metabolic condition or prevent further DM and vascular complications, such as glycemic control (assessed by HbA1c level), hypertension, and other risk factors for atherosclerosis (Becker and Nichols 2021).…”

Section: Treatmentmentioning

confidence: 99%

Diabetic Papillopathy: Diagnose and Treatment of A Rare Diabetes Mellitus Ocular Complication (A Literature Review)

Millenia¹,

Agustini²,

Susanto³

2022

IJRP

View full text Add to dashboard Cite

Diabetic papillopathy (DP) is a rare complication of DM that reduces the patient's visual function. Until now the lack number of studies, diagnosis, and treatment is still uncertain. Considering there still limitations of research on DP must continue to be explored as this literature is made. This study is a literature review that was carried out in 2022 to disclose more information on diabetic papillopathy. We searched for this topic using a systematic search of Google Scholar, PubMed, Scopus, Elsevier, and SAGE review databases. Some of the keywords we used for the literature search were "diabetes mellitus," "diabetic papillopathy," and "optic disc edema." To this end, this literature review aims to present, examine, diagnose, and treat diabetic papillopathy. DP has intravitreous clinical signs such as optic disc swelling or atrophy which have many differential diagnoses. To eliminate this differential diagnosis it is important for a doctor to understand the patient's history as DP is a manifestation of complications of metabolic disorders (hyperglycemia). Investigations include ophthalmological testing, MRI, neuroimaging, and clinical evaluation for infection signs will aid in determining the diagnosis of DP and discover optic nerve injury. It should be noted that, a better understanding of DP can determine an appropriate, effective, and plan B therapy modality.

show abstract

Diabetic papillopathy treated with intravitreal ranibizumab

Cited by 13 publications

References 10 publications

Bilateral hypertensive papillopathy with diffuse retinal telangiectasis

Bilateral hypertensive papillopathy with diffuse retinal telangiectasis

Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports

Diabetic Papillopathy: Diagnose and Treatment of A Rare Diabetes Mellitus Ocular Complication (A Literature Review)

Contact Info

Product

Resources

About